Scholars Central

EditorialPublished 28 Aug 2020

Updates on Long-Acting Injectable Antipsychotics

Authors: Peter F. Buckley

Clinical Schizophrenia & Related Psychoses

Volume 3 · Issue 2 · Pages 15–17

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

There have been several recent developments in the area of long-acting injectable antipsychotics. A Phase I study of a four-week long-acting injectable (LAI) formulation of risperidone has been commenced. The study will test the efficacy and tolerability of this four-week LAI formulation in twenty-six patients who have chronic schizophrenia. Risperidone microspheres, administered every two weeks, has been FDA-approved since 2003.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Clinical Schizophrenia & Related Psychoses.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Schizophrenia & Related Psychoses
  • SubjectMental Health and Psychology
  • BylineArticles whose byline prints “Peter F. Buckley”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels